A AngioDynamics anunciou que seu estudo de viabilidade Relief, que avalia a plataforma de eletroporação irreversível (IRE) Nanoknife como um tratamento minimamente invasivo para hiperplasia prostática benigna (HPB), recebeu aprovação de Isenção de Dispositivo Experimental (IDE) da Food and Drug Administration (FDA) dos EUA. – Bitget
AngioDynamics公司宣布，其用于评估Nanoknife不可逆电穿孔（IRE）平台作为良性前列腺增生（BPH）微创治疗方案的Relief可行性研究，已获得美国食品药品监督管理局（FDA）的研究用器械豁免（IDE）批准 Bitget
该文章暂未提取到完整正文，已从资讯列表和商品关联资讯中自动隐藏。你可以返回文章列表继续浏览其他内容。
Perguntas frequentes
Which products are related to this article?
No strongly related product has been identified yet. The match updates automatically when the article or catalog changes.
How can I view the medicines discussed in this article?
Use the related product cards below the article to review available specifications, prices, product information, and reviews.
Does this article replace advice from a doctor or pharmacist?
No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.
